A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of a Single Intravenous Infusion of TRP-8803 (Psilocin) in Healthy Adult Participants
This Phase I, open-label, dose-escalation study (n=9) aims to assess the safety and pharmacokinetics of a single intravenous infusion of psilocin (active metabolite of psilocybin; TRP-8803; 8-21mg) in healthy adult participants.